Tanusya Murali

I earned my Ph.D. from the National University of Singapore in 2022, where my research was on the characterization of anti-MHC I alloantibodies. As these molecules play a pivotal role in transplant rejection, we set out to dissect the different factors that influenced its pathogenicity. After completing my Ph.D., I embarked on a postdoctoral journey within the same laboratory. Our research focus shifted to antibodies targeting MHC II antigens, which are reported to be more detrimental. Simultaneously, I led a parallel project aimed at constructing an antibody phage library which will be a valuable platform for antibody discovery.

I joined Dr. Malcolm Sim’s lab in 2024 where my research focus will be on investigating the interaction between activating KIRs of NK cells with MHC-I molecules, and how it integrate signals to other NK cell receptors, including the inhibitory receptors.